HRP20040793A2 - Treating benign prostate hyperplasia with sarms - Google Patents

Treating benign prostate hyperplasia with sarms

Info

Publication number
HRP20040793A2
HRP20040793A2 HR20040793A HRP20040793A HRP20040793A2 HR P20040793 A2 HRP20040793 A2 HR P20040793A2 HR 20040793 A HR20040793 A HR 20040793A HR P20040793 A HRP20040793 A HR P20040793A HR P20040793 A2 HRP20040793 A2 HR P20040793A2
Authority
HR
Croatia
Prior art keywords
type
subject
sarm
analog
pharmaceutically acceptable
Prior art date
Application number
HR20040793A
Other languages
English (en)
Croatian (hr)
Inventor
Mitchell
A. Veverka Karen
D. Miller Duane
T. Dalton James
Gao Wenqing
Original Assignee
Gtx Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gtx Inc. filed Critical Gtx Inc.
Publication of HRP20040793A2 publication Critical patent/HRP20040793A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Surgical Instruments (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Steroid Compounds (AREA)
HR20040793A 2002-02-07 2004-09-01 Treating benign prostate hyperplasia with sarms HRP20040793A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35430002P 2002-02-07 2002-02-07
US36299702P 2002-03-11 2002-03-11
PCT/US2003/003447 WO2003065992A2 (fr) 2002-02-07 2003-02-06 Traitement de l'hyperplasie prostatique benigne a l'aide de modulateurs selectifs des recepteurs androgenes (sarm)

Publications (1)

Publication Number Publication Date
HRP20040793A2 true HRP20040793A2 (en) 2006-10-31

Family

ID=27737453

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20040793A HRP20040793A2 (en) 2002-02-07 2004-09-01 Treating benign prostate hyperplasia with sarms
HR20100067A HRP20100067A2 (hr) 2002-02-07 2010-04-15 Liječenje benigne hiperplazije prostate selektivnim modulatorima androgenih receptora

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20100067A HRP20100067A2 (hr) 2002-02-07 2010-04-15 Liječenje benigne hiperplazije prostate selektivnim modulatorima androgenih receptora

Country Status (21)

Country Link
US (2) US7776921B2 (fr)
EP (1) EP1480634B1 (fr)
JP (3) JP4677516B2 (fr)
KR (2) KR101032661B1 (fr)
CN (2) CN1646115B (fr)
AT (1) ATE518537T1 (fr)
AU (2) AU2003216174C1 (fr)
BR (1) BRPI0307699A2 (fr)
CA (2) CA2689080C (fr)
CY (1) CY1111917T1 (fr)
DK (1) DK1480634T3 (fr)
EA (2) EA013399B1 (fr)
GE (1) GEP20074122B (fr)
HK (1) HK1068103A1 (fr)
HR (2) HRP20040793A2 (fr)
IL (2) IL163380A (fr)
MX (1) MXPA04007639A (fr)
PT (1) PT1480634E (fr)
RS (1) RS69704A (fr)
TW (2) TW200918043A (fr)
WO (1) WO2003065992A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US7518013B2 (en) 2000-08-24 2009-04-14 University Of Tennessee Research Foundation Selective androgen receptor modulators
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
WO2004035739A2 (fr) * 2002-10-16 2004-04-29 Gtx, Inc. Traitement d'etats associes au deficit androgenique lie a l'age chez l'homme (adam) au moyen de composes sarm
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
DE602004026583D1 (de) * 2003-06-27 2010-05-27 Orion Corp Als androgenrezeptormodulatoren geeignete propionamidderivate
FI20030958A0 (fi) * 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
CN101721402B (zh) * 2003-10-14 2013-03-13 田纳西大学研究基金会 用选择性雄激素受体调节剂治疗骨相关病症
AP2006003700A0 (en) 2004-02-13 2006-08-31 Warner Lambert Co Androgen receptor modulators
CA2563291A1 (fr) * 2004-04-13 2005-10-27 Warner-Lambert Company Llc Derives de 4-cyanophenoxy-alkylcarboxyle comme modulateurs androgenes
WO2005102990A1 (fr) 2004-04-22 2005-11-03 Warner-Lambert Company Llc Modulateurs des androgenes
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
ES2640591T3 (es) * 2004-06-07 2017-11-03 University Of Tennessee Research Foundation Usos médicos de un modulador selectivo del receptor de andrógenos
GEP20094851B (en) * 2004-06-07 2009-12-10 The Univ Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
UA87854C2 (en) * 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
BRPI0513020A (pt) 2004-07-08 2008-04-22 Warner Lambert Co moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação
EP1768984B1 (fr) 2004-07-16 2010-10-20 Sunesis Pharmaceuticals, Inc. Thienopyrimidines utiles en tant qu'inhibiteurs des kinases aurora
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
EP2008099A4 (fr) * 2006-04-03 2009-12-23 Medexis S A Detection d'agents modulant les recepteurs d'androgene de membrane
EA016853B1 (ru) 2006-08-24 2012-08-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Замещенные ациланилиды и их применение
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
JP2015509538A (ja) * 2012-03-07 2015-03-30 リガンド・ファーマシューティカルズ・インコーポレイテッド １つに統合された恒常性システムとしてのステロイドホルモン経路およびコレステロール経路
WO2013152323A1 (fr) 2012-04-06 2013-10-10 Wotton Paul K Administration par injection par jet assistée par une aiguille de compositions de testostérone
EP3733170A1 (fr) 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. Procédé de traitement de cancers du sein positifs aux récepteurs des androgène (ar) à l'aide d'un modulateur sélectif des récepteurs androgènes (sarm)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
WO2015122858A1 (fr) 2014-02-15 2015-08-20 Erdal Can Alkoçlar Composition contenant des composants synthétiques formée pour supprimer la ribonucléotide réductase
HUP1400294A2 (hu) 2014-06-13 2015-12-28 Skillpharm Kft Clopidogrel új alkalmazása
US20160106702A1 (en) * 2014-10-16 2016-04-21 Gtx, Inc. METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US644970A (en) * 1899-02-06 1900-03-06 Thomas Graham Donaldson Dental flask.
US935044A (en) * 1909-01-12 1909-09-28 Lenn G Mccorry Valve.
US935045A (en) * 1909-06-19 1909-09-28 Robert J Mckelvey Turn-table.
GB1360001A (en) 1971-06-16 1974-07-17 Scherico Ltd Pharmaceutical compositions comprising substituted anilides
US3875229A (en) 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
JPS6044294B2 (ja) 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
EP0002309B1 (fr) 1977-10-12 1982-12-01 Imperial Chemical Industries Plc Acylanilides, procédé pour leur préparation et compositions pharmaceutiques et vétérinaires les contenant
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8617652D0 (en) 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
CA2181358A1 (fr) 1994-01-21 1995-07-27 Nancy M. Gray Procedes et compositions de traitement de maladies dependantes des androgenes a l'aide de r-(-)-casodex optiquement pur
US5609849A (en) 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
WO1998005962A1 (fr) 1996-08-02 1998-02-12 Panvera Corporation Procede de quantification de la fixation par competition de certaines molecules a des proteines en utilisant la polarisation de fluorescence
US20090264534A1 (en) * 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US7205437B2 (en) * 1996-11-27 2007-04-17 University Of Tennessee Research Foundation Selective androgen receptor modulators
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
JPH10182457A (ja) 1996-12-25 1998-07-07 Yuichi Hashimoto 抗アンドロゲン剤
WO1998053826A1 (fr) * 1997-05-30 1998-12-03 The University Of Tennessee Research Corporation Composes agonistes non steroidiens et leur utilisation dans le cadre de therapies a base d'hormones males
AU7723198A (en) * 1997-06-04 1998-12-21 University Of Tennessee Research Corporation, The Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
JPH1135558A (ja) 1997-07-18 1999-02-09 Zeria Pharmaceut Co Ltd ３−ベンゾイルインドール誘導体及びそれらを含有する医薬
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
EP1222459A4 (fr) 1999-10-14 2003-01-22 Bristol Myers Squibb Co Structure cristallographique du domaine de liaison du ligand du recepteur androgene
CZ20021340A3 (cs) 1999-10-19 2002-08-14 Nobex Corporation Způsoby asymetrické přípravy enantiomerů acylanilidů, jejich derivátů a meziproduktů pro uvedené přípravy
MXPA02004225A (es) 1999-10-27 2002-10-17 Nobex Corp Resolucion de intermediarios en la sintesis de bicalutamida sustancialmente pura.
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
US6960474B2 (en) 2000-06-28 2005-11-01 Bristol-Myers Squibb Company Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
IL154425A0 (en) 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
US20030232792A1 (en) 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
EA014224B1 (ru) 2000-08-24 2010-10-29 Юниверсити Оф Теннесси Рисерч Фаундейшн Селективные модуляторы андрогенового рецептора и способы их применения
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
AU2002364949C1 (en) 2001-12-06 2008-05-29 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators

Also Published As

Publication number Publication date
CA2689080C (fr) 2011-07-05
WO2003065992A3 (fr) 2004-02-26
BRPI0307699A2 (pt) 2015-06-16
US7776921B2 (en) 2010-08-17
US20040053897A1 (en) 2004-03-18
EA200401043A1 (ru) 2005-06-30
HK1068103A1 (en) 2005-04-22
TWI374737B (en) 2012-10-21
WO2003065992A2 (fr) 2003-08-14
TW200307537A (en) 2003-12-16
RS69704A (en) 2006-12-15
CN101732298B (zh) 2012-09-19
AU2003216174B2 (en) 2008-12-18
AU2003216174C1 (en) 2010-01-28
IL163380A (en) 2010-06-30
US20100280107A1 (en) 2010-11-04
JP2013144713A (ja) 2013-07-25
ATE518537T1 (de) 2011-08-15
GEP20074122B (en) 2007-06-11
EP1480634A2 (fr) 2004-12-01
CA2689080A1 (fr) 2003-08-14
US8088828B2 (en) 2012-01-03
HRP20100067A2 (hr) 2010-04-30
CN1646115B (zh) 2010-06-09
EA200901492A1 (ru) 2010-08-30
EP1480634A4 (fr) 2008-01-16
JP2010209102A (ja) 2010-09-24
AU2003216174B8 (en) 2009-01-15
IL202675A (en) 2011-06-30
AU2003216174A1 (en) 2003-09-02
KR20100112659A (ko) 2010-10-19
EA013399B1 (ru) 2010-04-30
CA2475108A1 (fr) 2003-08-14
EP1480634B1 (fr) 2011-08-03
TW200918043A (en) 2009-05-01
KR20040089606A (ko) 2004-10-21
AU2009201084A1 (en) 2009-04-09
CN1646115A (zh) 2005-07-27
KR101032661B1 (ko) 2011-05-06
JP2005522431A (ja) 2005-07-28
PT1480634E (pt) 2011-10-12
CN101732298A (zh) 2010-06-16
DK1480634T3 (da) 2011-11-14
CY1111917T1 (el) 2015-11-04
JP4677516B2 (ja) 2011-04-27
MXPA04007639A (es) 2005-07-13

Similar Documents

Publication Publication Date Title
HRP20040793A2 (en) Treating benign prostate hyperplasia with sarms
NO20043531L (no) Indazolforbindelser som er nyttige som proteinkinaseinhibitorer
DK1569899T3 (da) Substituerede 3-alkyl- og 3-arylalkyl-1H-indol-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
AU2002340010A1 (en) Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
NO982006L (no) Terapeutisk preparat for transdermal tilf°rsel av virksomme stoffer gjennom huden
NO20070372L (no) Amidoforbindelser og anvendelse derav som farmasoytiske preparater
IS6069A (is) N-cýanómetýlamíð sem próteasalatar
DE60142921D1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
NO20012977L (no) N-ureidoalkylpiperidiner som modulatorer av chemokinreseptoraktivitet
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
NO308037B1 (no) 16-substituerte-4-aza-androstan 5<alfa>-reduktase-isoenzym 1- inhibitorer og farmasøytisk preparat
NO20030961L (no) Farmasöytiske preparater samt metode for behandling av hypogonadisme
DK0841904T3 (da) Orale farmaceutiske præparater med forsinket frigivelse af reversible protonpumpeinhibitorer
DK1420645T3 (da) Topisk afgivelsessystem i form af en multivesikulær emulsion
NO20055957L (no) Metode for behandling av aterosklerose, dyslipidemi og beslektede tilstander, og farmasoytiske preparater
WO2004064735A3 (fr) Traitement de l'hypertrophie prostatique benigne
NO20080417L (no) Benzosykloheptapyridiner som inhibitorer av reseptortyrosinkinasen MET
WO2000007576A3 (fr) INHIBITION DE LA 3$G(a)-HYDROXYSTEROID-DESHYDROGENASE DE TYPE 3
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
WO2004052236A3 (fr) Methodes et compositions de traitement de l'otite moyenne
WO2005016327A3 (fr) Traitement de troubles du sommeil a l'aide d'inhibiteurs de la cholinesterase
WO2001056555A3 (fr) Utilisation d'inhibiteurs de cox-2 dans le traitement de la constipation
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
PT2061444E (pt) Composições e métodos de tratamento, controlo, redução, melhoramento ou prevenção de alergias
DK0984936T3 (da) Cyanoguanidiner som celleproliferationsinhibitorer

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20120111

Year of fee payment: 10

OBST Application withdrawn